Adma Biologics (ADMA) Gross Profit: 2011-2025
Historic Gross Profit for Adma Biologics (ADMA) over the last 12 years, with Sep 2025 value amounting to $75.6 million.
- Adma Biologics' Gross Profit rose 26.76% to $75.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $267.3 million, marking a year-over-year increase of 42.70%. This contributed to the annual value of $219.6 million for FY2024, which is 146.85% up from last year.
- Adma Biologics' Gross Profit amounted to $75.6 million in Q3 2025, which was up 12.49% from $67.2 million recorded in Q2 2025.
- Adma Biologics' Gross Profit's 5-year high stood at $75.6 million during Q3 2025, with a 5-year trough of -$1.7 million in Q1 2021.
- Over the past 3 years, Adma Biologics' median Gross Profit value was $57.5 million (recorded in 2024), while the average stood at $46.6 million.
- Per our database at Business Quant, Adma Biologics' Gross Profit crashed by 114.50% in 2021 and then skyrocketed by 2,406.02% in 2022.
- Quarterly analysis of 5 years shows Adma Biologics' Gross Profit stood at $3.5 million in 2021, then surged by 303.76% to $14.2 million in 2022, then soared by 119.27% to $31.1 million in 2023, then soared by 103.73% to $63.3 million in 2024, then increased by 26.76% to $75.6 million in 2025.
- Its last three reported values are $75.6 million in Q3 2025, $67.2 million for Q2 2025, and $61.1 million during Q1 2025.